UCB (OTCMKTS:UCBJY) Upgraded at Wolfe Research

Wolfe Research upgraded shares of UCB (OTCMKTS:UCBJY) to a strong-buy rating in a report issued on Monday,Zacks.com reports.

UCBJY has been the topic of several other research reports. Jefferies Financial Group raised UCB to a “moderate sell” rating in a research note on Sunday, October 26th. Zacks Research cut UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy”.

UCB Price Performance

UCB stock opened at $159.42 on Monday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.35 and a quick ratio of 1.01. The firm has a 50-day moving average of $151.23 and a two-hundred day moving average of $138.00. UCB has a 1 year low of $71.16 and a 1 year high of $168.76.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.